Literature DB >> 1737785

Thyroid hormone stimulation of NADPH P450 reductase expression in liver and extrahepatic tissues. Regulation by multiple mechanisms.

P A Ram1, D J Waxman.   

Abstract

The role of thyroid hormone in regulating the expression of the flavoprotein NADPH cytochrome P450 reductase was studied in adult rats. Depletion of circulating thyroid hormone by hypophysectomy, or more selectively, by treatment with the anti-thyroid drug methimazole led to a 75-85% depletion of hepatic microsomal P450 reductase activity and protein in both male and female rats. Thyroxine substantially restored P450 reductase activity at a dose that rendered the thyroid-depleted rats euthyroid. Microsomal P450 reductase activity in several extrahepatic tissues was also dependent on thyroid hormone, but to a lesser extent than in liver (30-50% decrease in kidney, adrenal, lung, and heart but not in testis from hypothyroid rats). Hepatic P450 reductase mRNA levels were also decreased in the hypothyroid state, indicating that the loss of P450 reductase activity is not a consequence of the associated decreased availability of the FMN and FAD cofactors of P450 reductase. Parallel analysis of S14 mRNA, which has been studied extensively as a model thyroid-regulated liver gene product, indicated that P450 reductase and S14 mRNA respond similarly to these changes in thyroid state. In contrast, while the expression of S14 and several other thyroid hormone-dependent hepatic mRNAs is stimulated by feeding a high carbohydrate, fat-free diet, hepatic P450 reductase expression was not increased by this lipogenic diet. Injection of hypothyroid rats with T3 at a supraphysiologic, receptor-saturating dose stimulated a major induction of hepatic P450 reductase mRNA that was detectable 4 h after the T3 injection, and peaked at approximately 650% of euthyroid levels by 12 h. However, this same treatment stimulated a biphasic increase in P450 reductase protein and activity that required 3 days to reach normal euthyroid levels. T3 treatment of euthyroid rats also stimulated a major induction of P450 reductase mRNA that was maximal (12-fold increase) by 12 h, but in this case no major increase in P450 reductase protein or activity was detectable over a 3-day period. Together, these studies establish that thyroid hormone regulates P450 reductase expression by pretranslational mechanisms. They also suggest that other regulatory mechanisms, which may involve changes in P450 reductase protein stability and/or changes in the translational efficiency of its mRNA, are likely to occur.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737785

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Regulation of NADPH-cytochrome P450 reductase expressed during Douglas-fir germination and seedling development.

Authors:  T J Tranbarger; B S Forward; S Misra
Journal:  Plant Mol Biol       Date:  2000-09       Impact factor: 4.076

2.  Prolonged sedation due to an accumulation of midazolam in an intensive care patient with hypothyroidism.

Authors:  M Bolon; O Bastien; C Flamens; R Boulieu
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

3.  Consequences of POR mutations and polymorphisms.

Authors:  Walter L Miller; Vishal Agrawal; Duanpen Sandee; Meng Kian Tee; Ningwu Huang; Ji Ha Choi; Kari Morrissey; Kathleen M Giacomini
Journal:  Mol Cell Endocrinol       Date:  2010-11-09       Impact factor: 4.102

4.  Peri- and postnatal changes in reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase content in hepatocytes of rats.

Authors:  J Watanabe; Y Asaka; S Kanamura
Journal:  Histochem J       Date:  1996-07

5.  Adaptive hepatic and intestinal alterations in mice after deletion of NADPH-cytochrome P450 Oxidoreductase (Cpr) in hepatocytes.

Authors:  Xingguo Cheng; Jun Gu; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2014-08-21       Impact factor: 3.922

6.  Oxidative stress signaling underlying liver disease and hepatoprotective mechanisms.

Authors:  Luis A Videla
Journal:  World J Hepatol       Date:  2009-10-31

7.  Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms.

Authors:  Meng Kian Tee; Ningwu Huang; Izabella Damm; Walter L Miller
Journal:  Mol Endocrinol       Date:  2011-03-10

8.  Pathophysiological changes that affect drug disposition in protein-energy malnourished children.

Authors:  Kazeem A Oshikoya; Idowu O Senbanjo
Journal:  Nutr Metab (Lond)       Date:  2009-12-01       Impact factor: 4.169

9.  Intensification of doxorubicin-related oxidative stress in the heart by hypothyroidism is not related to the expression of cytochrome P450 NADPH-reductase and inducible nitric oxide synthase, as well as activity of xanthine oxidase.

Authors:  Jaroslaw Dudka; Franciszek Burdan; Agnieszka Korga; Magdalena Iwan; Barbara Madej-Czerwonka; Monika Cendrowska-Pinkosz; Agnieszka Korobowicz-Markiewicz; Barbara Jodlowska-Jedrych; Wlodzimierz Matysiak
Journal:  Oxid Med Cell Longev       Date:  2012-08-23       Impact factor: 6.543

10.  Hepatic dysfunction in hospitalized patients with acute thyrotoxicosis: a decade of experience.

Authors:  Richard M Elias; Diana S Dean; Gregory W Barsness
Journal:  ISRN Endocrinol       Date:  2012-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.